Cumberland Pharmaceuticals Launches RediTrex Product Line for Active Rheumatoid Arthritis, Juvenile Idiopathic Arthritis and Severe Psoriatic Arthritis

0

NASHVILLE, Tennessee.Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced the national launch of its RediTrex (methotrexate) line of pre-filled syringes designed for the simple and safe treatment of active rheumatoid arthritis, juvenile idiopathic arthritis and severe psoriatic arthritis .

An FDA approved injectable methotrexate (MTX), RediTrex is designed for easy handling and dosing accuracy, resulting in increased efficacy, higher patient continuation rates, and less discomfort. RediTrex treats patients with severe and active rheumatoid arthritis and polyarticular juvenile idiopathic arthritis who have difficulty tolerating or responding to oral MTX. It is also approved for the symptomatic control of severe, recalcitrant and disabling psoriasis in adults who do not respond adequately to other forms of treatment.

“RediTrex is available in eight strengths and is designed for subcutaneous injection,” said AJ Kazimi, CEO of Cumberland Pharmaceuticals. “The pre-filled syringes ensure accurate and safe dosing and feature an extra-fine 29-gauge automatic retractable needle to reduce pain and the risk of needle sticks. They also have a large handle and a concave plunger that allow patients with limited dexterity to self-administer the injection at a controlled rate. RediTrex offers these benefits while being less expensive than auto-injectors. ‘

With more than 54 million Americans living with some form of arthritis, the disease is one of the most common causes of incapacity for work in the we, according to CDC. The oral form of MTX is usually the first line of treatment for rheumatoid arthritis. As the disease progresses the dose must be increased to remain effective, often causing intolerable gastrointestinal side effects. Injectable MTX, like RediTrex, has been shown to be more effective than oral MTX, with fewer gastrointestinal side effects. Due to its increased efficacy and tolerance, Injectable MTX may delay the switch to expensive biologics, thereby reducing the overall costs of treating patients. Once disease progression requires the use of biologics, continued treatment with MTX Injectable with the biologic has been shown to increase overall effectiveness.

The other injectable MTX options available may not optimally meet the needs of a patient with arthritis. Patients are offered either a vial and syringe for self-injection or the use of an expensive auto-injector. The vial and syringe method can be difficult for a patient to handle due to limited hand dexterity. Additionally, getting the exact dose needed while preventing skin exposure to caustic MTX can be quite difficult for patients. Auto-injectors provide a better alternative to the vial and syringe, but they take away the control of the patient’s injection and can be painful to administer. They are also the most expensive MTX delivery.

For more information about RediTrex, including complete prescribing and safety data, visit www.reditrex.com.

On Cumberland Pharmaceuticals:

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on delivering branded prescription products to improve patient care. The Company develops, acquires and markets brands for the acute hospital care, gastroenterology and rheumatoid arthritis markets.

The Company’s portfolio of FDA-approved brands include: acetadote injection (acetylcysteine), for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Omeclamox-Pak (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and associated duodenal ulcer; RediTrex (methotrexate) Injection, for the treatment of active rheumatoid arthritis, juvenile idiopathic and severe psoriatic arthritis, as well as disabling psoriasis; Vaprisol (conivaptan) injection, to increase serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) Injection, for the treatment of certain serious bacterial infections, including nosocomial and ventilation-associated bacterial pneumonia, as well as complicated infections of the skin and skin structures.

The Company also has ongoing Phase II clinical programs evaluating its product candidates in patients with cardiomyopathy associated with Duchenne muscular dystrophy as well as patients with systemic sclerosis and respiratory disease exacerbated by aspirin.

For more information on Cumberland’s approved products, including full prescribing information, please visit the links to the individual product websites, which can be found on the company’s website at www.cumberlandpharma .com.

Forward-looking statements

This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland’s current views on future events based on what it considers reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland’s business are subject to factors beyond its control, and any or a combination of these factors could have a material effect on Cumberland’s results of operations. These factors include market conditions, competition, inability of manufacturers to produce Cumberland’s products on a timely basis or failure to comply with regulations applicable to pharmaceutical manufacturers, maintenance of a sales and marketing infrastructure. effective, natural disasters, public health epidemics, and other events beyond our control, as further explained in the Company’s most recent Form 10-K and subsequent 10-Qs filed with the SECOND. There can be no assurance that the results anticipated by the Company will be achieved or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to publicly revise these statements to reflect events subsequent to the date hereof.

Contact:

Investor

Shayla simpson

Cumberland Pharmaceuticals

Phone. : (615) 255-0068

Media

Molly aggas

Dalton Agency

T: (704) 641-6641

Bailee Mulder

Dalton Agency

Phone. : (615) 515-4885


Source link

Share.

Leave A Reply